{"brief_title": "Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes", "brief_summary": "The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to rosiglitazone in lowering overall blood glucose levels in people with type 2 diabetes who have not previously been treated with drug therapy to lower their blood sugar.", "condition": ["Diabetes Mellitus, Type 2"], "intervention_type": ["Drug"], "intervention_name": ["vildagliptin"], "criteria": "Inclusion Criteria: - Blood glucose criteria must be met - Not currently on drug therapy for type 2 diabetes - Body mass index (BMI) in the range 22-45 Exclusion Criteria: - Pregnancy or lactation - Type 1 diabetes - Evidence of serious diabetic complications - Evidence of serious cardiovascular conditions - Laboratory value abnormalities as defined by the protocol - Other protocol-defined exclusion criteria may apply", "gender": "All", "minimum_age": "18 Years", "maximum_age": "80 Years", "healthy_volunteers": "No", "keyword": "vildagliptin", "mesh_term": ["Diabetes Mellitus", "Diabetes Mellitus, Type 2", "Vildagliptin", "Rosiglitazone"], "id": "NCT00099918"}